| 1 |
35631502 | Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions. | 2022 Apr 22 |
2 |
| 2 |
32970826 | Clopidogrel Dosing: Current Successes and Emerging Factors for Further Consideration. | 2021 May |
1 |
| 3 |
33270185 | Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention. | 2021 Apr |
1 |
| 4 |
33931001 | Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment. | 2021 Jun |
1 |
| 5 |
34690774 | The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction. | 2021 |
2 |
| 6 |
32932966 | Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. | 2020 Sep 11 |
2 |
| 7 |
33519456 | Physiologically-Based Pharmacokinetic-Pharmacodynamics Model Characterizing CYP2C19 Polymorphisms to Predict Clopidogrel Pharmacokinetics and Its Anti-Platelet Aggregation Effect Following Oral Administration to Coronary Artery Disease Patients With or Without Diabetes. | 2020 |
1 |
| 8 |
29696643 | Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. | 2019 Jan |
1 |
| 9 |
29998574 | CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel. | 2019 Feb |
1 |
| 10 |
30361928 | In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel. | 2019 Apr |
1 |
| 11 |
30609441 | Influence of Amlodipine on Haemostatic Measurements during Clopidogrel Treatment in Patients with Coronary Artery Disease. | 2019 Feb |
1 |
| 12 |
30648733 | Effectiveness and Safety of Clopidogrel Co-administered With Statins and Proton Pump Inhibitors: A Korean National Health Insurance Database Study. | 2019 Jul |
2 |
| 13 |
30993551 | Inhibitory Effect of Vonoprazan on the Metabolism of [14C]Prasugrel in Human Liver Microsomes. | 2019 Oct |
1 |
| 14 |
31102151 | Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel. | 2019 Aug |
1 |
| 15 |
28875498 | Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype. | 2018 May |
1 |
| 16 |
30422888 | Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance. | 2018 Dec |
1 |
| 17 |
26891871 | Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. | 2017 Feb |
3 |
| 18 |
27904973 | Platelet reactivity and clinical outcomes in patients using CYP3A4-metabolized statins with clopidogrel in percutaneous coronary intervention. | 2017 Jun |
5 |
| 19 |
27133299 | Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. | 2016 Jul |
1 |
| 20 |
27196064 | The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway. | 2016 Dec |
1 |
| 21 |
27350760 | Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention. | 2016 |
1 |
| 22 |
27556885 | Plasma miR-142 accounting for the missing heritability of CYP3A4/5 functionality is associated with pharmacokinetics of clopidogrel. | 2016 Sep |
4 |
| 23 |
29767595 | Gene polymorphism of CYP2C19*2, *3 and CYP3A4*1B and early stent thrombosis: case reports and literature review. | 2016 Sep |
1 |
| 24 |
25747989 | Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin. | 2015 |
2 |
| 25 |
26329790 | Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin. | 2015 Nov |
1 |
| 26 |
26767297 | [Computational Pharmacological Study on Clopidogrel Metabolism Enzymes Influenced by Fufang Danshen Dripping Pill]. | 2015 May |
3 |
| 27 |
24719135 | Antiplatelet effect of clopidogrel can be reduced by calcium-channel blockers. | 2014 May |
1 |
| 28 |
24986003 | [Practical questions on therapy with new antithrombotic agents]. | 2014 Apr |
1 |
| 29 |
23400261 | CYP3A4 genetic status may be associated with increased vulnerability to the inhibitory effect of calcium-channel blockers on clopidogrel. | 2013 |
4 |
| 30 |
23770199 | Hepatocellular toxicity of clopidogrel: mechanisms and risk factors. | 2013 Dec |
12 |
| 31 |
23773422 | Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences. | 2013 Dec |
5 |
| 32 |
24023447 | Clopidogrel and the possibility of drug-drug interaction in primary health care. | 2013 Mar |
3 |
| 33 |
21834799 | Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events. | 2012 Mar |
1 |
| 34 |
22243420 | Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation. | 2012 Jul |
1 |
| 35 |
22313038 | Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. | 2012 Jul |
2 |
| 36 |
22319066 | Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. | 2012 Feb 1 |
1 |
| 37 |
22428615 | The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro. | 2012 Aug |
2 |
| 38 |
22507978 | Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. | 2012 Sep |
2 |
| 39 |
22613391 | [Comparison on the effects of clopidogrel, statins combination in treating coronary artery disease among the elderly patients: a retrospective cohort study]. | 2012 Mar |
1 |
| 40 |
22651985 | Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: importance of metabolites. | 2012 Sep 28 |
1 |
| 41 |
22735685 | Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. | 2012 Sep |
2 |
| 42 |
24900388 | Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation. | 2012 Oct 11 |
2 |
| 43 |
20980920 | The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. | 2011 Jan |
1 |
| 44 |
21568918 | Interactions between clopidogrel and proton pump inhibitors: a review of evidence. | 2011 |
1 |
| 45 |
21826477 | Thienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance. | 2011 Oct |
1 |
| 46 |
21828263 | Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro. | 2011 Nov |
1 |
| 47 |
19636246 | Clopidogrel pharmacogenetics and its clinical implications. | 2010 May-Jun |
1 |
| 48 |
19812348 | Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. | 2010 Jan |
1 |
| 49 |
20664903 | A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial. | 2010 Sep |
1 |
| 50 |
20735423 | Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. | 2010 Sep |
7 |